Antiviral Drug Market
Antiviral Drug Market Size, Share & Trends Analysis Report by Drug Class (Protease Inhibitors, Integrease Strand Transfer Inhibitors (INSTIs), Entry & Fusion Inhibitors, Neuraminidase Inhibitors, RNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Combination Antiviral Therapies), by Indication (HIV/AIDS, Hepatitis, Influenza, Herpes Simplex Virus, Human Papillomavirus), by Drug Type (Small Molecules Antivirals, Biologics, RNA Based Therapies ), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Forecast Period (2026–2035)
Industry Overview
Global antiviral drug market was valued at $61.2 billion in 2025 and is projected to reach $90.6 billion by 2035, growing at a CAGR of 4.0 % from 2026 to 2035. The antiviral drugs market represents a vital component of the global healthcare system, focusing on the prevention and treatment of viral infections such as HIV, influenza, hepatitis, and other emerging infectious diseases. According to the Centers for Disease Control and Prevention, antiviral drugs are prescription medicines that work by inhibiting the replication of viruses, thereby reducing the severity and duration of illness. These drugs are widely used in both acute and chronic infections and are considered an essential complement to vaccination programs, particularly for diseases like influenza, where timely treatment can reduce complications and hospitalisations. Government health agencies also emphasise early initiation of antiviral therapy, especially for high-risk populations, to improve clinical outcomes and limit disease progression. Antiviral drugs are available in various formulations, including oral, inhaled, and intravenous forms, enabling flexible treatment across different patient groups and healthcare settings.
The growth of the antiviral drugs market is strongly influenced by the rising global burden of viral diseases and increasing government focus on public health preparedness. Data from the World Health Organisation indicates that millions of people globally continue to live with chronic viral infections such as HIV, requiring lifelong antiviral therapy, while seasonal influenza causes millions of severe cases annually. Governments and regulatory bodies such as the US Food and Drug Administration play a critical role in accelerating the approval and monitoring of antiviral drugs, ensuring their safety and effectiveness. In addition, public health initiatives, antiviral stockpiling strategies, and increased funding for infectious disease research have strengthened the development and availability of these drugs. The continued emergence of new viral threats and the need for rapid response mechanisms further highlight the importance of antiviral therapies, making them a key focus area for healthcare systems and policy frameworks worldwide.
Market Dynamics
Rising Burden of Viral Diseases
The antiviral drugs market is driven by the rising burden of viral infections and strong government healthcare initiatives, while also facing challenges such as drug resistance and strict regulations. According to the World Health Organisation, seasonal influenza alone results in around 1 billion cases annually, including 3–5 million severe cases, significantly increasing the demand for antiviral treatments. Government agencies like the Centers for Disease Control and Prevention emphasise that antiviral drugs are essential for treatment, especially for high-risk populations, and early use can reduce complications and mortality. However, the market faces restraints due to antiviral drug resistance, as viruses continuously mutate and can reduce drug effectiveness over time. At the same time, opportunities are expanding through increased use of antivirals for prevention and pandemic preparedness programs supported by governments. Additionally, regulatory bodies such as the U.S. Food and Drug Administration enforce strict approval processes, which ensure safety but can delay market entry. Overall, rising disease burden, government support, and ongoing innovation continue to shape the growth dynamics of the antiviral drugs market.
High Development Costs and Resistance Challenges Restraining Growth
Despite strong growth prospects, the antiviral drug market faces significant challenges. High research and development costs, lengthy approval timelines, and stringent regulatory requirements create barriers for new entrants. According to Evaluate Pharma, drug development costs often exceed $2 billion per successful molecule, making antiviral innovation capital-intensive. Additionally, viral mutations and drug resistance reduce the long-term effectiveness of therapies, especially in HIV and influenza treatment. Supply chain disruptions and raw material shortages also impact production, particularly for biologics and RNA-based drugs. However, companies are increasingly adopting advanced manufacturing technologies and AI-driven drug discovery to mitigate these challenges and improve efficiency.
Growing Domestic Production and Innovative Processes Strengthen China's Antiviral Drug Industry
China is expected to witness rapid growth in the antiviral drug market due to expanding healthcare infrastructure and increasing disease burden. According to the Organisation for Economic Co-operation and Development, China’s healthcare spending has grown significantly over the past decade. The country is also investing heavily in pharmaceutical manufacturing and biotechnology research. Rising domestic demand, coupled with export opportunities, is boosting the antiviral drug market. Government initiatives to improve healthcare access and promote local drug production further support growth.
Market Segmentation
- Based on drug class, the market is segmented into protease inhibitors, integrase strand transfer inhibitors, reverse transcriptase inhibitors, entry & fusion inhibitors, neuraminidase inhibitors, RNA polymerase inhibitors, and combination antiviral therapies.
- Based on the indication, the market is segmented into HIV/AIDS, hepatitis, influenza, herpes simplex virus, and human papillomavirus.
- Based on drug type, the market is segmented into small-molecule antivirals, biologics, and RNA-based therapies.
- Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Reverse Transcriptase Inhibitors Segment Leads the Market
The Reverse Transcriptase Inhibitors (RTIs) segment dominates the antiviral drug market due to its widespread use in HIV treatment. RTIs, including NRTIs and NNRTIs, form the backbone of antiretroviral therapy (ART), which is essential for managing HIV infections globally. According to the World Health Organisation, ART coverage continues to expand, with millions of patients receiving treatment annually. This has significantly increased demand for RTIs. Pharmaceutical companies have focused on developing combination regimens and long-acting injectable RTIs to improve patient adherence. Between 2022 and 2026, multiple product launches and partnerships strengthened the market presence of this segment.
RNA-based Therapies Segment to Record Strong Growth
The RNA-based therapies segment is expected to witness the fastest growth due to technological advancements in mRNA and siRNA platforms. These therapies offer targeted antiviral action and faster development timelines compared to traditional drugs. The success of mRNA-based vaccines has accelerated research into RNA-based antivirals. According to the World Intellectual Property Organisation, patent filings for RNA therapeutics have increased significantly in recent years. Investments in biotechnology and collaborations between pharmaceutical companies and research institutions are driving innovation in this segment. Emerging applications in hepatitis and respiratory infections are expected to further boost growth.
Regional Outlook
The global Antiviral Drugs Market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Is Leading the Global Antiviral Drug Market
North America dominates the global antiviral drugs market, primarily due to the strong healthcare infrastructure and high disease burden in the United States. Government data from the Centers for Disease Control and Prevention shows that viral infections such as HIV remain a persistent public health concern, with 31,800 new HIV infections reported in 2022. Additionally, the CDC highlights that millions of people continue to require ongoing antiviral treatment and monitoring through national surveillance systems. The region also benefits from strong government initiatives such as the national strategy to end the HIV epidemic by 2030, which focuses on expanding treatment access and prevention programs. These factors—high disease prevalence, continuous government funding, and advanced research infrastructure—significantly increase the demand for antiviral drugs, making North America the leading region in the global antiviral drugs market.
Asia-Pacific to Emerge as the Fastest-Growing Region
Asia-Pacific, including key markets such as China, India, Japan, and South Korea, is the fastest-growing region due to a large patient population, increasing incidence of viral diseases, and improving healthcare access. Government initiatives for disease control, expanding generic drug manufacturing (especially in India), and rising healthcare expenditure are key growth drivers. Moreover, increasing awareness, vaccination programs, and investments in biotechnology and pharmaceutical sectors are accelerating antiviral drug adoption across the region.
Market Players Outlook
The antiviral drugs market is characterised by the presence of several global pharmaceutical and biotechnology companies that focus on continuous innovation, drug development, and strategic collaborations to strengthen their market position. Leading companies such as Gilead Sciences, Inc., Pfizer lnc, GlaxoSmithKline plc, Merck & Co., Inc., and Johnson & Johnson play a key role in shaping the market landscape. These companies are investing significantly in research and development to improve drug efficacy, enhance treatment outcomes, and reduce resistance in viral infections. Additionally, they are focusing on advanced antiviral therapies such as direct-acting antivirals (DAAs), combination therapies, and novel biologics to support growing demand from sectors including infectious disease treatment, pandemic preparedness, hospital care, and public health programs.
Recent Development
- In November 2025, Merck reported positive Phase 3 results for its investigational Doravirine/Islatravir (DOR/ISL), a once-daily oral HIV treatment, showing comparable efficacy to standard therapies.
- In June 2025, Gilead announced that the U.S. FDA approved lenacapavir (Yeztugo®), the first twice-yearly injectable antiviral for HIV prevention. This breakthrough offers protection for up to 6 months, significantly improving patient adherence compared to daily pills.
- In June 2025, AbbVie announced that the U.S. FDA approved an expanded indication for its direct-acting antiviral MAVYRET (glecaprevir/pibrentasvir), making it the first and only DAA regimen approved to treat acute hepatitis C virus (HCV) infection in an 8-week course. This approval strengthens AbbVie’s position in the HCV antiviral drugs segment.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualised market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global antiviral drug Market.
- Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Antiviral Drug Market Sales Analysis – Drug Class| Distribution Channel| Drug type| Indication ($ Million)
- Antiviral Drug Market Sales Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Antiviral Drug Market Trends
- Market Recommendations
- Market Determinants
- Market Drivers
- Drivers for Global Antiviral Drug Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints for Global Antiviral Drug Market: Impact Analysis
- Market Opportunities
- Opportunities for the Antiviral Drug Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Antiviral Drug Market Revenue and Share by Manufacturers
- Antiviral Drugs Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Pfizer
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Johnson & Johnson
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Gilead Sciences
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Merck & Co
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- GSK (Glaxosmithkline)
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer
- Key Company Analysis
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Global Antiviral Drug Market Sales Analysis by Drug Class ($ Million)
- Protease Inhibitors
- Integrase Strand Transfer Inhibitors
- Entry & Fusion Inhibitors
- Neuraminidase Inhibitors
- RNA Polymers-based Inhibitors
- Combination Antiviral Therapies
- Reverse Transcriptase Inhibitors
- Global Antiviral Drug Market Sales Analysis by Indication ($ Million)
- HIV/AIDS
- Hepatitis
- Influenza
- Herpes Simplex Virus (HSV)
- Human Papillomavirus (HPV)
- Others
- Global Antiviral Drug Market Sales Analysis by Drug Type ($ Million)
- Small Molecule Antivirals
- Biologics Antivirals
- RNA – Based Therapies
- Global Antiviral Drug Market Sales Analysis by Distribution Channel ($ Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Analysis
- North American Antiviral Drug Market Sales Analysis – Drug Type | Indication | Drug Class | Distribution Channel | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Antiviral Drug Market Sales Analysis – Drug Type | Indication | Drug Class | Distribution Channel | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Antiviral Drug Market Sales Analysis – Drug Type | Indication | Drug Class | Distribution Channel | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Antiviral Drug Market Sales Analysis – Drug Type | Indication | Drug Class | Distribution Channel | Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
10.1. AbbVie
10.1.1. Overview
10.1.2. Product Portfolio
10.1.3. Financial Analysis
10.1.4. SWOT Analysis
10.1.5. Business Strategy
10.2. Alnylam Pharmaceuticals
10.2.1. Overview
10.2.2. Product Portfolio
10.2.3. Financial Analysis
10.2.4. SWOT Analysis
10.2.5. Business Strategy
10.3. Arrowhead Pharmaceuticals
10.3.1. Overview
10.3.2. Product Portfolio
10.3.3. Financial Analysis
10.3.4. SWOT Analysis
10.3.5. Business Strategy
10.4. Assembly Biosciences
10.4.1. Overview
10.4.2. Product Portfolio
10.4.3. Financial Analysis
10.4.4. SWOT Analysis
10.4.5. Business Strategy
10.5. AstraZeneca
10.5.1. Overview
10.5.2. Product Portfolio
10.5.3. Financial Analysis
10.5.4. SWOT Analysis
10.5.5. Business Strategy
10.6. Bayer
10.6.1. Overview
10.6.2. Product Portfolio
10.6.3. Financial Analysis
10.6.4. SWOT Analysis
10.6.5. Business Strategy
10.7. BioNTech
10.7.1. Overview
10.7.2. Product Portfolio
10.7.3. Financial Analysis
10.7.4. SWOT Analysis
10.7.5. Business Strategy
10.8. Boehringer Ingelheim
10.8.1. Overview
10.8.2. Product Portfolio
10.8.3. Financial Analysis
10.8.4. SWOT Analysis
10.8.5. Business Strategy
10.9. Bristol-Myers Squibb (BMS)
10.9.1. Overview
10.9.2. Product Portfolio
10.9.3. Financial Analysis
10.9.4. SWOT Analysis
10.9.5. Business Strategy
10.10. Eli Lilly and Company
10.10.1. Overview
10.10.2. Product Portfolio
10.10.3. Financial Analysis
10.10.4. SWOT Analysis
10.10.5. Business Strategy
10.11. Enanta Pharmaceuticals
10.11.1. Overview
10.11.2. Product Portfolio
10.11.3. Financial Analysis
10.11.4. SWOT Analysis
10.11.5. Business Strategy
10.12. Moderna
10.12.1. Overview
10.12.2. Product Portfolio
10.12.3. Financial Analysis
10.12.4. SWOT Analysis
10.12.5. Business Strategy
10.13. Novartis
10.13.1. Overview
10.13.2. Product Portfolio
10.13.3. Financial Analysis
10.13.4. SWOT Analysis
10.13.5. Business Strategy
10.14. Regeneron Pharmaceuticals
10.14.1. Overview
10.14.2. Product Portfolio
10.14.3. Financial Analysis
10.14.4. SWOT Analysis
10.14.5. Business Strategy
10.15. Roche (F. Hoffmann-La Roche)
10.15.1. Overview
10.15.2. Product Portfolio
10.15.3. Financial Analysis
10.15.4. SWOT Analysis
10.15.5. Business Strategy
10.16. Sanofi
10.16.1. Overview
10.16.2. Product Portfolio
10.16.3. Financial Analysis
10.16.4. SWOT Analysis
10.16.5. Business Strategy
10.17. Shionogi & Co.
10.17.1. Overview
10.17.2. Product Portfolio
10.17.3. Financial Analysis
10.17.4. SWOT Analysis
10.17.5. Business Strategy
10.18. Takeda Pharmaceutical
10.18.1. Overview
10.18.2. Product Portfolio
10.18.3. Financial Analysis
10.18.4. SWOT Analysis
10.18.5. Business Strategy
10.19. ViiV Healthcare
10.19.1. Overview
10.19.2. Product Portfolio
10.19.3. Financial Analysis
10.19.4. SWOT Analysis
10.19.5. Business Strategy
10.20. Vir Biotechnology
10.20.1. Overview
10.20.2. Product Portfolio
10.20.3. Financial Analysis
10.20.4. SWOT Analysis
10.20.5. Business Strategy
1. Global Antiviral Drug Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
2. Global Polymerase Inhibitors Antiviral Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Integrase Strand Transfer Inhibitors Antiviral Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Entry & Fusion Inhibitors Antiviral Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Neuraminidase Inhibitors Antiviral Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global RNA Polymers-based Inhibitors Antiviral Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Combination Antiviral Therapies Antiviral Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Reverse Transcriptase Inhibitors Antiviral Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Antiviral Drug Research and Analysis by Indication, 2025–2035 ($ Million)
10. Global Antiviral Drug for HIV/AIDS Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Antiviral Drug for Hepatitis Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Antiviral Drug for Influenza Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Antiviral Drug for Herpes Simplex Virus Research and Analysis by Region, 2025–2035 ($ Million)
14. Global Antiviral Drug for Human Papillomavirus Research and Analysis by Region, 2025–2035 ($ Million)
15. Global Antiviral Drug for Others Research and Analysis by Region, 2025–2035 ($ Million)
16. Global Antiviral Drug Market Research and Analysis by Drug Type, 2025–2035 ($ Million)
17. Global Small Molecule Antivirals Antiviral Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
18. Global Biologics / Antibody-based Antivirals Antiviral Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
19. Global RNA-based Therapies Antiviral Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
20. Global Antiviral Drug Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
21. Global Hospital Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
22. Global Retail Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
23. Global Online Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
24. Global Antiviral Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
25. North America Antiviral Drug Market Research and Analysis by Country, 2025–2035 ($ Million)
26. North America Antiviral Drug Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
27. North America Antiviral Drug Market Research and Analysis by Indication, 2025–2035 ($ Million)
28. North America Antiviral Drug Market Research and Analysis by Drug Type, 2025–2035 ($ Million)
29. North America Antiviral Drug Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
30. Europe Antiviral Drug Market Research and Analysis by Country, 2025–2035 ($ Million)
31. Europe Antiviral Drug Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
32. Europe Antiviral Drug Market Research and Analysis by Indication, 2025–2035 ($ Million)
33. Europe Antiviral Drug Market Research and Analysis by Drug Type, 2025–2035 ($ Million)
34. Europe Antiviral Drug Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
35. Asia-Pacific Antiviral Drug Market Research and Analysis by Country, 2025–2035 ($ Million)
36. Asia-Pacific Antiviral Drug Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
37. Asia-Pacific Antiviral Drug Market Research and Analysis by Indication, 2025–2035 ($ Million)
38. Asia-Pacific Antiviral Drug Market Research and Analysis by Drug Type, 2025–2035 ($ Million)
39. Asia-Pacific Antiviral Drug Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
40. Rest of the World Antiviral Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
41. Rest of the World Antiviral Drug Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
42. Rest of the World Antiviral Drug Market Research and Analysis by Indication, 2025–2035 ($ Million)
43. Rest of the World Antiviral Drug Market Research and Analysis by Drug Type, 2025–2035 ($ Million)
44. Rest of the World Antiviral Drug Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
1. Global Antiviral Drug Market Share by Drug Class, 2025 Vs 2035 (%)
2. Global Polymerase Inhibitors Antiviral Drug Market Share by Region, 2025 Vs 2035 (%)
3. Global Integrase Strand Transfer Inhibitors Antiviral Drug Market Share by Region, 2025 Vs 2035 (%)
4. Global Entry & Fusion Inhibitors Antiviral Drug Market Share by Region, 2025 Vs 2035 (%)
5. Global Neuraminidase Inhibitors Antiviral Drug Market Share by Region, 2025 Vs 2035 (%)
6. Global RNA Polymers-based Inhibitors Antiviral Drug Market Share by Region, 2025 Vs 2035 (%)
7. Global Protease Inhibitors Antiviral Drug Market Share by Region, 2025 Vs 2035 (%)
8. Global Combination Antiviral Therapies Antiviral Drug Market Share by Region, 2025 Vs 2035 (%)
9. Global Reverse Transcriptase Inhibitors Antiviral Drug Market Share by Region, 2025 Vs 2035 (%)
10. Global Antiviral Drug Market Share by Indication, 2025 Vs 2035 (%)
11. Global Antiviral Drug for HIV/AIDS Share by Region, 2025 Vs 2035 (%)
12. Global Antiviral Drug for Hepatitis Share by Region, 2025 Vs 2035 (%)
13. Global Antiviral Drug for Influenza Share by Region, 2025 Vs 2035 (%)
14. Global Antiviral Drug for Herpes Simplex Virus Share by Region, 2025 Vs 2035 (%)
15. Global Antiviral Drug for Human Papillomavirus Share by Region, 2025 Vs 2035 (%)
16. Global Antiviral Drug for Respiratory Viral Infections Share by Region, 2025 Vs 2035 (%)
17. Global Antiviral Drug for Others Share by Region, 2025 Vs 2035 (%)
18. Global Antiviral Drug Market Share by Drug Type, 2025 Vs 2035 (%)
19. Global Small Molecule Antivirals Antiviral Drug Market Share by Region, 2025 Vs 2035 (%)
20. Global Biologics / Antibody-based Antivirals Antiviral Drug Market Share by Region, 2025 Vs 2035 (%)
21. Global RNA-based Therapies Antiviral Drug Market Share by Region, 2025 Vs 2035 (%)
22. Global Antiviral Drug Market Share by Distribution Channel, 2025 Vs 2035 (%)
23. Global Hospital Pharmacies Antiviral Drug Market Share by Region, 2025 Vs 2035 (%)
24. Global Retail Pharmacies Antiviral Drug Market Share by Region, 2025 Vs 2035 (%)
25. Global Online Pharmacies Antiviral Drug Market Share by Region, 2025 Vs 2035 (%)
26. Global Antiviral Drug Market Share by Region, 2025 Vs 2035 (%)
27. United States Antiviral Drug Market Size, 2025–2035 ($ Million)
28. Canada Antiviral Drug Market Size, 2025–2035 ($ Million)
29. UK Antiviral Drug Market Size, 2025–2035 ($ Million)
30. France Antiviral Drug Market Size, 2025–2035 ($ Million)
31. Germany Antiviral Drug Market Size, 2025–2035 ($ Million)
32. Italy Antiviral Drug Market Size, 2025–2035 ($ Million)
33. Spain Antiviral Drug Market Size, 2025–2035 ($ Million)
34. Russia Antiviral Drug Market Size, 2025–2035 ($ Million)
35. India Antiviral Drug Market Size, 2025–2035 ($ Million)
36. China Antiviral Drug Market Size, 2025–2035 ($ Million)
37. Japan Antiviral Drug Market Size, 2025–2035 ($ Million)
38. South Korea Antiviral Drug Market Size, 2025–2035 ($ Million)
39. Australia & New Zealand Antiviral Drug Market Size, 2025–2035 ($ Million)
40. ASEAN Antiviral Drug Market Size, 2025–2035 ($ Million)
41. Rest of Asia-Pacific Antiviral Drug Market Size, 2025–2035 ($ Million)
42. Latin America Antiviral Drug Market Size, 2025–2035 ($ Million)
43. Middle East & Africa Antiviral Drug Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
